About the Company
Novavax, Inc. is an American biotechnology company based in Gaithersburg, Maryland, that develops vaccines to counter serious infectious diseases. Prior to 2020, company scientists developed experimental vaccines for influenza and respiratory syncytial virus (RSV), as well as Ebola and other emerging infectious diseases. During 2020, the company redirected its efforts to focus on development and approval of its NVX-CoV2373 vaccine for COVID-19. The COVID-19 vaccine Nuvaxovid was approved in the European Union at the end of 2021, and in Canada in February 2022, as the fifth vaccine against COVID-19, following Pfizer/BioNTech, Moderna, Janssen and AstraZeneca.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on NOVAVAX INC
Novavax Strengthens Position with Vaccine Approval and Sanofi Partnership
Novavax, Inc. (NASDAQ:NVAX) is a biotechnology company focused on recombinant protein-based vaccines using nanoparticle and ...
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know
Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...
Novavax, Inc. (NASDAQ:NVAX) Q2 2025 Earnings Call Transcript
Q2 2025 Earnings Call Transcript August 6, 2025 Novavax, Inc. beats earnings expectations. Reported EPS is $0.601, ...
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is ... - Nasdaq
Novavax reported revenues of $415.48 million in the last reported quarter, representing a year-over-year change of -2.1%. EPS of $0.99 for the same period compares with $0.58 a year ago.
Novavax Ditches 'Going Concern,' Embraces Sanofi Safety Net (Rating ...
While Novavax, Inc. has gained visibility, this remains a risky investment. Its stock is extremely volatile (24M beta of 1.99), and its 5-year return of 49.79% does not inspire confidence.
U.S. FDA Removes Clinical Hold on Novavax's COVID-19-Influenza ...
--Novavax, Inc., a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the U.S. Food and Drug Administration has removed the clinical hold on ...
Novavax’s Updated Covid Shot Falls Short of Original
Novavax Inc. shares fell after the company released data showing its current Covid-19 vaccine produced a better immune response than an experimental bivalent shot that targets omicron variants.
Novavax seeks FDA emergency use authorization for Covid-19 vaccine ...
Gaithersburg’s Novavax Inc. has submitted its long-awaited request for approval in the U.S. for its experimental Covid-19 vaccine, following several months of manufacturing delays and buildup ...
Novavax COVID shot, aimed at vaccine skeptics, overwhelmingly backed by ...
Advisers to the U.S. Food and Drug Administration on Tuesday voted overwhelmingly to recommend that the agency authorize Novavax Inc's COVID-19 vaccine for use in adults, which the drugmaker hopes ...
Novavax Vaccine Data Impresses In Variant Fight - Bloomberg
Novavax’s shot has been beset by delays and setbacks, but new data suggests it is a highly effective shot that could play a big role in the global pandemic fight.
Novavax forecasts higher-than-expected revenue; shares surge
COVID-19 vaccine maker Novavax Inc on Tuesday forecast much higher 2023 revenue than Wall Street expected and announced plans to cut a quarter of its workforce, spurring hopes of a recovery for ...
Similar Companies
Loading the latest forecasts...